Syngene tests investor appetite for IPO
Parent Biocon hopes the CRO's strong growth profile and expansion plans will mitigate recent downturn in the Indian equity market
May 15, 2015
Indian pharma company Biocon launched a Rs5.28 billion to Rs5.5 billion ($82.2 million to $85.7 million) initial public offering in its clinical research arm Syngene International on Monday.
Registered users get 2 free articles in 30 days.
Subscribers have full unlimited access to FinanceAsia.
Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.
Questions?
See here for more information on licences and prices, or contact [email protected].